Genomic Biomarkers Associated with the Risk of Sulfasalazine-Induced Drug Eruptions

Authors

Koya Fukunaga (ORCID: https://orcid.org/0000-0002-5241-6062)
Taisei Mushiroda (ORCID: https://orcid.org/0000-0002-4139-8794)

Institutions

RIKEN Center for Integrative Medical Sciences (JP)

Publication Details

Journal: Major Histocompatibility Complex
Published: 2025-01-01
DOI: https://doi.org/10.12667/mhc.32.37
Primary Topic: Drug-Induced Adverse Reactions
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Genomic Biomarkers Associated with the Risk of Sulfasalazine-Induced Drug Eruptions

Koya Fukunaga, Taisei Mushiroda

Jan 1, 2025

Major Histocompatibility Complex

Drug-Induced Adverse Reactions

article

Genomic Biomarkers Associated with the Risk of Sulfasalazine-Induced Drug Eruptions

Koya Fukunaga, Taisei Mushiroda

January 1, 2025article en

Abstract

No abstract available for this paper.

Major Histocompatibility ComplexVol. 32(2)

RIKEN Center for Integrative Medical Sciences (JP)

Good health and well-being

Openalex Percentile: Top 75%

Drug-Induced Adverse Reactions

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Genomic Biomarkers Associated with the Risk of Sulfasalazine-Induced Drug Eruptions — Koya Fukunaga, Taisei Mushiroda · Major Histocompatibility Complex (2025) | TGRS Research Map | TGRS